Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.003
-0.007 (-0.67%)
Mar 31, 2025, 2:20 PM EDT - Market open
Opus Genetics Revenue
Opus Genetics had revenue of $3.87M in the quarter ending September 30, 2024, a decrease of -67.60%. This brings the company's revenue in the last twelve months to $8.38M, down -85.35% year-over-year. In the year 2023, Opus Genetics had annual revenue of $19.05M, down -52.20%.
Revenue (ttm)
$8.38M
Revenue Growth
-85.35%
P/S Ratio
3.00
Revenue / Employee
$598,643
Employees
14
Market Cap
45.11M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IRD News
- 6 hours ago - Opus Genetics Announces Financial Results for Full Year 2024 - GlobeNewsWire
- 9 days ago - Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics - GlobeNewsWire
- 10 days ago - Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX - GlobeNewsWire
- 10 days ago - Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million - GlobeNewsWire
- 11 days ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - GlobeNewsWire
- 4 weeks ago - Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs - GlobeNewsWire
- 5 weeks ago - Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program - GlobeNewsWire